The KRAS Inhibitor market size is anticipated to increase in the study period due to a direct consequence of an increase in R&D activity in the 7MM. Additionally, the competitive landscape is relatively sparse and the regulatory pathway for approval will likely involve extensive clinical trials to demonstrate safety and efficacy.
DelveInsight’s KRAS Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS Inhibitors, market share of individual therapies, and current and forecasted KRAS Inhibitor market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the KRAS Inhibitor Market Report
- As per DelveInsight’s analysis, the KRAS Inhibitor market is anticipated to grow at a significant CAGR by 2032.
- Leading KRAS Inhibitor companies such as Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, ImmuneeringCorporation, Jacobio Pharmaceuticals, Bridge BioPharma (NavirePharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, Inventis Bio, Gritstone Bio, D3Bio, and others are developing novel KRAS Inhibitors that can be available in the KRAS Inhibitor market in the coming years.
- Some of the key KRAS Inhibitors include KRAZATI, LUMAKRAS, JDQ443, Onvansertib, and others.
Discover which therapies are expected to grab the KRAS Inhibitor market share @ KRAS Inhibitor Market Report
KRAS Inhibitor Overview
KRAS inhibitors were an area of intense research and development in the field of oncology. KRAS (Kirsten rat sarcoma viral oncogene homolog) is a proto-oncogene that plays a crucial role in regulating cell growth and division. Mutations in the KRAS gene are frequently found in various cancers, making it an attractive target for cancer therapies.
KRAS mutations are common in several cancer types, including colorectal cancer, lung cancer, and pancreatic cancer.
Mutant KRAS has been historically considered challenging to target directly, and finding effective inhibitors has been a significant focus of research.
Efforts to develop KRAS inhibitors gained momentum with advancements in understanding the structure and function of the KRAS protein.
Small molecules and biologics have been explored as potential KRAS inhibitors.
One subtype of KRAS mutations is G12C, and specific inhibitors have been developed to target this mutation. AMG 510 (sotorasib) is an example of a G12C-specific KRAS inhibitor that has shown promise in clinical trials, particularly in non-small cell lung cancer (NSCLC).
Several KRAS inhibitors have entered clinical trials to evaluate their safety and efficacy in different cancer types.
Trials have focused on both monotherapy and combination approaches, including combinations with other targeted therapies or immunotherapies.
Learn more about the FDA-approved KRAS Inhibitor @ KRAS Inhibitor Drugs
Key KRAS Inhibitor Therapies and Companies
- KRAZATI – Mirati Therapeutics
- LUMAKRAS – Amgen
- JDQ443 – Novartis
- Onvansertib – CARDIFF ONCOLOGY
To know more about KRAS Inhibitor clinical trials, visit @ KRAS Inhibitor Treatment Drugs
KRAS Inhibitor Treatment Market
The market landscape for KRAS inhibitors was actively evolving with ongoing clinical trials and research. Predicting the precise market landscape for the next few years involves considering various factors that influence the development, approval, and adoption of KRAS inhibitors.
Combination therapies involving KRAS inhibitors, either with other targeted therapies or immunotherapies, could become a significant trend. Synergistic effects observed in combination treatments may impact market dynamics.
Ongoing research may lead to the discovery and development of new KRAS inhibitors. The introduction of novel agents with improved efficacy or safety profiles could reshape the competitive landscape.
|
KRAS Inhibitor Report Metrics |
Details |
|
Study Period |
2019–2032 |
|
KRAS Inhibitor Report Coverage |
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
|
Key KRAS Inhibitor Companies |
Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, ImmuneeringCorporation, Jacobio Pharmaceuticals, Bridge BioPharma (NavirePharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, Inventis Bio, Gritstone Bio, D3Bio, and others |
|
Key KRAS Inhibitors |
KRAZATI, LUMAKRAS, JDQ443, Onvansertib, and others |
Scope of the KRAS Inhibitor Market Report
- KRAS Inhibitor Therapeutic Assessment: KRAS Inhibitor current marketed and emerging therapies
- KRAS Inhibitor Market Dynamics: Attribute Analysis of Emerging KRAS Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, KRAS Inhibitor Market Access and Reimbursement
Discover more about KRAS Inhibitor drugs in development @ KRAS Inhibitor Clinical Trials
Table of Contents
|
1. |
KRAS Inhibitor Market Key Insights |
|
2. |
KRAS Inhibitor Market Report Introduction |
|
3. |
KRAS Inhibitor Market Overview at a Glance |
|
4. |
KRAS Inhibitor Market Executive Summary |
|
5. |
Disease Background and Overview |
|
6. |
KRAS Inhibitor Treatment and Management |
|
7. |
KRAS Inhibitor Epidemiology and Patient Population |
|
8. |
Patient Journey |
|
9. |
KRAS Inhibitor Marketed Drugs |
|
10. |
KRAS Inhibitor Emerging Drugs |
|
11. |
Seven Major KRAS Inhibitor Market Analysis |
|
12. |
KRAS Inhibitor Market Outlook |
|
13. |
Potential of Current and Emerging Therapies |
|
14. |
KOL Views |
|
15. |
Unmet Needs |
|
16. |
SWOT Analysis |
|
17. |
Appendix |
|
18. |
DelveInsight Capabilities |
|
19. |
Disclaimer |
|
20. |
About DelveInsight |
Related Reports
KRAS Inhibitors Market
KRAS Inhibitors Market Insights, Epidemiology and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
TIGIT Inhibitors Competitive Landscape
TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.
Checkpoint Inhibitors Competitive Landscape
Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeBetter Med, BIOCAD, CanBas Co., Ltd., Laekna Therapeutics, Genentech, Alphamab Oncology, Hangzhou Sumgen Biotech, Harbour BioMed, Aurigene Discovery Technologies, BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, among others.
PD-1 and PD-L1 Inhibitors Competitive Landscape
PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/